Bristol Myers BMY+1.06% signed a deal worth potentially up to $11.1 billion for a new cancer medicine developed by BioNTech, joining the hottest rivalry in the US pharmaceutical industry.
Source: https://www.barrons.com/articles/bristol-myers-stock-biontech-cancer-f327b0ee